Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

NCT04707547 is registered in ClinicalTrials.gov with Taipei Medical University WanFang Hospital as lead sponsor.

NCT NCT04707547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04707547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
Lead sponsor
Taipei Medical University WanFang Hospital
Phase
Phase 4
Overall status
Completed
Start date
October 16, 2019
Completion date
July 23, 2020
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer